Status:
COMPLETED
The Effects of Protein Supplementation in Females and Males Following Acute Eccentric Exercise
Lead Sponsor:
Liverpool John Moores University
Conditions:
Muscle Damage
Eligibility:
All Genders
18-35 years
Phase:
NA
Brief Summary
Examine the impact of the protein supplements leucine, HMB and BCAA on muscle recovery and inflammatory response following acute exercise.
Detailed Description
Participants, both females and males, will perform an acute bout of exercise. A bout of exercise that will involve multiple drop jumps. Prior to and post exercise, functional outputs will be measured ...
Eligibility Criteria
Inclusion
- Health recreationally active males and females.
Exclusion
- Asthma sufferers
- People with kidney disease
- People partaking in lower limb strength training
- People suffering DOMS in the past 6 months
- People already taking dietary supplements, other NSAIDs, or for example aspirin, alcohol, warfarin, phenytoin, methotrexate, lithium, diuretics, cyclosporine.
- People with bone or soft tissue injury within last 12 months
- People with gastric problems
- People with hypertension
- People who have had history of heart failure
- People with liver disease
- People with connective tissue disorders
- People with Crohn's disease
- People with ulcerative colitis
- People with peripheral arterial disease
- People with cerebrovascular disease
- Elderly population
- People with allergies to NSAIDs, Omega- 3 fatty acids and BCAAs.
- People with depression
- People with bipolar disorder
- People with diabetes
- Females who are pregnant
- People who have HIV / AIDS
Key Trial Info
Start Date :
March 6 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 25 2019
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04679519
Start Date
March 6 2017
End Date
March 25 2019
Last Update
January 6 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Liverpool John Moores University
Liverpool, Merseyside, United Kingdom, L3 3AF